- Screener
- Securities US
- Amgen Inc
Amgen Inc
$273.68
-$3.46
-1.25%
21 Apr 20:00
$253.30
$346.85
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
weak bearish sentiment increases
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
-1.03Sentiment
BearishStart Date
04.04.2025Duration
13Yield
-5.75%Avg.Yield
-2.12%
Volatility
1.82%Max MDD
-5.58%Avg. MDD
-9.29%Min Price
RUB 277.29Max Price
RUB 295.30
Protective stop levels
S/L 5%RUB 291.15 | S/L 10%RUB 305.02 | S/L 15%RUB 318.88 | |
|---|---|---|---|
Day | 0.73% | 0.00% | 0.00% |
Week | 23.00% | 1.90% | 0.06% |
Month | 55.81% | 25.26% | 9.34% |
Technical analysis
- Trend ClassTurning down
- Trend PowerSlow trend
- PatternChannel
- EMA-20Bearish reversal2025-04-04 the price crossed down the moving average line and demonstrates a strong downside trend.
- EMA-50Bearish reversal2025-04-04 the price crossed down the moving average line and formed a short-term downside trend.
- EMA-100Bearish reversal2025-04-04 the price crossed down the moving average line and formed a short-term downside trend.
- StochasticBearish reversalThe stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.
- RSIBearish recoveryRSI indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.
- MACDBearish recoveryOscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.
- Candle pattern typeBullish EngulfingIs characterized by a large white body engulfing a preceding smaller black body, which appears during a downtrend. Considered to be a bullish reversal pattern.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 2.65% | 4.11% | $268.50 | $278.68 | 507.73M |
| Week | -3.14% | 1.96% | $268.50 | $296.17 | 1.44B |
| Month | -9.92% | 0.15% | $267.40 | $317.59 | 7.90B |
| 3 Months | 3.57% | 5.36% | $267.40 | $335.88 | 24.49B |
| 6 Months | -10.12% | 19.73% | $253.30 | $335.88 | 51.44B |
| Year | 5.82% | 0.64% | $253.30 | $346.85 | 83.43B |
| 3 years | 11.45% | 56.01% | $211.71 | $346.85 | 226.50B |
| 5 years | 23.47% | 76.51% | $198.64 | $346.85 | 383.47B |
| All time | 2,341.12% | 54.85% | $11.66 | $346.85 | 360.28B |
Volatility
| AMGN | By industry | |
|---|---|---|
| Yesterday | 36.85% | 1.03% |
| Week | 2.72% | 1.76% |
| Month | 13.66% | 9.54% |
| 3 Months | 15.46% | 20.61% |
| 6 Months | 19.20% | 29.79% |
| Year | 27.65% | 41.76% |
| 3 years | 40.93% | 90.20% |
| 5 years | 52.73% | 117.61% |
| All time | — | — |
- Sortino
- 0.15
- Sharpe
- 0.18
- Sterling
- -0.15
- Liquidity index
- 7.09
- Alpha
- 0.00015
- Beta
- 0.34
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$149.09B
Capitalization
537.65M
Shares outstanding
Health Care
Sector
Biotechnology
Industry
US0311621009
ISIN
1
Lot size
Mr. Robert A. Bradway
CEO
Website
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.